Research recommendation(s) from an individual piece of guidance
|Guidance:||Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)|
|Date issued:||May 2005|
Research recommendations coming out of this guidance
- [NICE] noted the need for research on further platinum-based combinations [for second-line or subsequent treatment of advanced ovarian cancer].
- [NICE] recommends that a study be undertaken to investigate the effectiveness of single-agent non-platinum therapy compared with platinum alone or in combination with paclitaxel, as second-line treatments for patients with platinum-sensitive [advance
- [NICE] noted the lack of data on the health-related quality of life of women with ovarian cancer and recommends that these data are collected
This page was last updated: 20 March 2014